UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000021677 |
|---|---|
| Receipt number | R000024998 |
| Scientific Title | the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab |
| Date of disclosure of the study information | 2016/03/31 |
| Last modified on | 2018/09/10 14:15:16 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab
Acronym
the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab
Scientific Title
the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab
Scientific Title:Acronym
the utility of dynamic contrase-enhanced MRI for advanced and metastatic breast cancer administerd with bevacizumab
Region
| Japan |
Condition
Condition
breast cancer
Classification by specialty
| Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
I clarify whether an objective evaluation of the blood vessel permeability using DCEMRI can become the clinical predictive factor of bevacizumab
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
the rates of change for Ktrans using DCEMRI from first time to second time
Key secondary outcomes
progression free survival
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
administration with paclitaxel and bevacizumab
paclitaxel 90mg/m2 day1,8,15
Bevacizumab 10mg/kg day1,15
1cycle for 21days continue to progression
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | >= |
Gender
Female
Key inclusion criteria
1)histologically confirmed breast cancer
2)age more than 20 and below 80
3)PS(ECOG)0-1
4)survival period more than 6 months
5)no effect remain from prior chemotherapy
6)adequate organ function
WBC>=4000/mm3
Neu>=2000/mm3
Hb>=9.0g/dL
Plt>=100000/mm3
sT-Bil<=1.5mg/dL
AST<=100IU/L
ALT<=100IU/L
Cr>=60ml/min
7)written informed consent
Key exclusion criteria
1)be pregnant or possible to pregnancy
2)with active breast cancer
3)with severe complications
4)with uncontrolled pleural effusion,ascites and edema
5)with brain metastasis
6)doctor's decision not to be registered to this study
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tetsuya Taguchi |
Organization
kyoto prefectural university of medicine
Division name
Dept of Endocrine and Breast surgery
Zip code
Address
465-kajii cho,kawaramachi-hirokoji,kamigyo-ku,kyoto-city,602-8566
TEL
0752515534
breast@koto.kpu-m.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | katsuhiko nakatsukasa |
Organization
kyoto prefectural university of medicine
Division name
Dept of Endocrine and Breast surgery
Zip code
Address
465-kajii cho,kawaramachi-hirokoji,kamigyo-ku,kyoto-city,602-8566
TEL
075-251-5534
Homepage URL
kacchan@koto.kpu-m.ac.jp
Sponsor or person
Institute
kyoto prefectural university of medicine
Institute
Department
Personal name
Funding Source
Organization
self funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 03 | Month | 31 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 11 | Month | 27 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 01 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 03 | Month | 30 | Day |
Last modified on
| 2018 | Year | 09 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024998
